Third quarter revenues increased 36% compared to 3Q24 Third quarter net loss of $0.032 per share QUÉBEC CITY / Jun 26, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), today announced financial results for its third quarter ended on April 30, 2025. Management Comments “ The operating cash flows generated by Altius revenues continued to support the development... Read More

QUÉBEC CITY / Jun 09, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the appointment of Dr. André Boulet as Chief Executive Officer of the Corporation, replacing Mr. Luc Gregoire who will continue in the new role of Executive Vice-President... Read More

QUEBEC CITY / Apr 28, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), announced that the TSX Venture Exchange (the “ Exchange ”) has approved its application for reinstatement of trading of the Company's common shares on the Exchange effective April 30, 2025. This follows the successful resolution of the Failure-to-File Cease Trade Order (the “ FFCTO ”) issued... Read More

Second quarter revenue increased 275% year over year Second quarter net loss of $0.001 per share Debt repaid in full QUEBEC CITY / Apr 15, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), today announced financial results for its second quarter ended on January 31, 2025. Management Comments “ Devonian continued to improve its financial position in the second... Read More

QUEBEC CITY / Apr 14, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), announces that the Autorité des Marchés Financiers (the “ AMF ”) has issued a failure to file cease trade order (“ FFCTO ”) under Policy Statement 11-207 Respecting Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions , prohibiting the trading by any person of any... Read More

QUÉBEC CITY / Apr 01, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced a delay, beyond the prescribed date limit, in filing its unaudited quarterly financial statements for the second quarter ended January 31, 2025 and the related management... Read More

QUEBEC CITY / Mar 24, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases held its annual general and special meeting of shareholders on March 20, 2025 (the “ Meeting ”) online via live webcast. The Corporation reported that shareholders voted on, and approved, the... Read More

QUEBEC CITY / Feb 19, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new patent application directed to the use of Thykamine™ as an antifibrotic agent. Backed by in vivo data, the patent application displays the potential effectiveness of... Read More

QUEBEC CITY / Feb 13, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new provisional patent application directed to the use of Thykamine™ for treating metabolic dysfunction-associated steatotic liver disease (MASLD), such as MASH. Backed by... Read More

Positive results from the STAM mouse model in vivo study attributing Thykamine™ with anti-MASH and anti-fibrosis effects in liver Compelling results compared to Resmetirom, the first FDA approved drug for management of MASH QUEBEC CITY / Feb 13, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions... Read More

QUEBEC CITY / Feb 07, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced that its pharmaceutical distribution division, Altius Healthcare Group L.P. (" Altius "), has been informed that one of its licensor does not intend to exercise its contractual... Read More

In vitro study demonstrated superior potency of Thykamine™ against various corticosteroids and a phosphodiesterase inhibitor Supports the clinical efficacy results of Thykamine™ in previous and ongoing studies in the treatment of various autoimmune inflammatory diseases QUEBEC CITY / Feb 04, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage... Read More

QUEBEC CITY / Jan 21, 2025 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the appointment of Ms. Viktoria Krasteva as Chief Financial Officer of the Corporation and the newest member of the corporate leadership team. Ms. Krasteva is scheduled to begin... Read More

First quarter revenues increased by 360% year over year First quarter net loss for the quarter of $0.002 per share Grant of 1,535,715 stock options to independent directors QUEBEC CITY / Dec 23, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), today announced financial results for its first quarter ended on October 31, 2024. Management Comments “ Devonian... Read More

Fourth quarter revenues of $9 Million increased 749% year over year Annual revenues of $17.8 Million increased 660% year over year Fourth quarter net income of $0.007 per share Annual net loss of $0.008 per share QUEBEC CITY / Nov 29, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXv: GSD ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique... Read More

QUEBEC CITY / Oct 08, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXv: GSD ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces that its Board of Directors has approved the grant of options to purchase Shares (the “ Options ”) at an exercise price of $0.16 for a period... Read More

QUEBEC CITY / Oct 07, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ) announced that it is amending its articles of amalgamation (the " Amended Articles "), in accordance with the approval by the shareholders at the Annual General and Special Meeting held on February 20, 2024. Devonian currently has one class of shares listed on the TSX Venture Exchange (the... Read More

QUEBEC CITY / Jul 15, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), announced today that they will be participating in Renmark Financial Communications Inc.’s (“ Renmark ”) live Virtual Non-Deal Roadshow Series in Chicago on July 17, 2024, to discuss its latest investor presentation. Devonian welcomes stakeholders, investors, and other individual followers to... Read More

QUEBEC CITY / Jul 08, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series in Los Angeles on July 10, 2024 to discuss its latest investor presentation. Devonian welcomes stakeholders, investors, and other individual followers to register... Read More

QUEBEC CITY / Jun 25, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series in Boston on June 26, 2024 to discuss its latest investor presentation. Devonian welcomes stakeholders, investors, and other individual followers to register and... Read More

Third quarter revenues increased 1,162% year over year Third quarter net loss for the quarter of $ 0.002 per share Renmark Financial Communications selected for investor relations QUEBEC CITY / Jun 25, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), today announced financial results for its third quarter ended on April 30, 2024. Management Comments “ This has... Read More

MONTREAL / Jun 03, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that Dr. André P. Boulet has been appointed as the Chair of the Board of Directors (the "Board") of the Corporation and... Read More

QUEBEC CITY / Mar 28, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), today announced financial results for its second quarter ended on January 31, 2024. Management Comments " This has been a truly transformative quarter for Devonian ,” said Luc Gregoire, President and CEO of Devonian. “ While shoring up our organization structure and focusing our activities... Read More

QUEBEC CITY / Mar 14, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced that it has closed its non-brokered previously announced private placement for aggregate gross proceeds of $223,800.00 (the “... Read More

QUEBEC CITY / Feb 29, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the board of directors of the Corporation (the “ Board ”) has appointed pharmaceutical industry veteran Ms. Kathryn... Read More

QUÉBEC CITY / Feb 27, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that its wholly-owned subsidiary, Altius Healthcare Inc. (“ Altius ”), has launched the first authorized generic... Read More

QUEBEC CITY / Feb 26, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that it has entered into a twelve (12) month term loan in a principal of $2,160,000 (the “ Loan ”) from Fiera Private... Read More

QUEBEC CITY / Feb 21, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the results of the vote of its annual general and extraordinary shareholders' meeting (the “ Meeting ”) held on February... Read More

QUÉBEC, Québec / Feb 20, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced that the United States Patent and Trademark Office (“ USPTO ”) has issued patent no. 11,723,938 B2 entitled, “ Thylakoid... Read More

QUEBEC CITY / Jan 19, 2024 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that during its general annual and special meeting of shareholders (the “ Meeting ”), which will be held virtually... Read More

Luc Grégoire, current Director of Devonian, appointed as President and CEO, brings 30 years of financial capital markets, strategic and operational leadership David Baker transitions from board director with appointment as non-executive Chairman of the Board of Directors QUÉBEC CITY / Dec 04, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Company ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage... Read More

QUÉBEC CITY / Nov 08, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXv: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that the Corporation has filed a Patent Cooperation Treaty ( PCT ) patent application for seeking protection for... Read More

QUEBEC CITY / Sep 01, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceeds of $499,999.94 (the “ Offering... Read More

QUEBEC CITY / Jun 20, 2023 / Business Wire / Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB : DVHGF), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, , is pleased to announce that the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for Devonian’s Patent... Read More

QUEBEC CITY / Jun 06, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed its non-brokered previously announced private placement for aggregate gross proceeds of... Read More

QUEBEC CITY / May 19, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce its intention to complete a non-brokered private placement with investors relying on prospectus exemption pursuant... Read More

QUEBEC CITY / May 16, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXv: GSD; OTCQB : DVHGF ), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced that results from phase 2 clinical study in mild-to-moderate atopic dermatitis (‘‘ AD ’’) will be presented at the... Read More

QUEBEC CITY / May 12, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXv: GSD; OTCQB : DVHGF ), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today that Mr David Baker, Edouard Dahl and Jean Forcione were appointed as a new independent directors to the Company’s... Read More

QUEBEC CITY / May 11, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has filed and obtained a receipt for its preliminary short form base shelf prospectus (“ Preliminary Shelf... Read More

QUEBEC CITY / Mar 30, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that at the annual and special meeting of its shareholders on March 17, 2023 (the “ Meeting ”), shareholders... Read More

QUEBEC CITY / Mar 24, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXv: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the voting results of its Annual General and Special Meeting held on March 17, 2023 in person and via videoconferencing.... Read More

QUEBEC CITY / Feb 22, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXv: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that its Hybrid Annual General and Special Meeting of shareholders will take place on March 17, 2023, at 14:00 p.m.... Read More

QUEBEC CITY / Jan 26, 2023 / Business Wire / Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXv: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that Mr. Pierre Montanaro, President and Chief Executive Officer of the Corporation, is scheduled to present at... Read More

Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXv: GSD; OTCQB: DVHGF ), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today executive changes within Devonian, its subsidiary Altius Healthcare inc. (‘‘ Altius ’’) and grant of options to directors and a consultant. As Altius enters a new... Read More